Asia Pacific Generic Oncology Sterile Injectable Market to Surpass US$ 8,832.6 Million by 2028

Asia Pacific Generic Oncology Sterile Injectable Market, by Drug Type (Monoclonal Antibodies, Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific), is estimated to be valued at US$ 4,055.3 million in 2021 and is expected to exhibit a CAGR of 12.2% during the forecast period (2021-2028).

Increasing incidence of cancer in Asia Pacific region is expected to augment the growth of Asia Pacific generic oncology sterile injectable market over the forecast period. According to Cancer Australia in 2017, estimated number of new cancer cases diagnosed were pegged at 134,174 in Australia, supporting the demand for generic oncology sterile injectable in Australia. The new cases of various cancers diagnosed in Australia in 2017 are given in the table below:

Breast

17,730

Colorectal

16,682

Prostate (among males)

16,665

Melanoma13,941Lung12,434

Asia Pacific Generic Oncology Sterile Injectable Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256.4 million cases and 5.1 million deaths due to coronavirus (COVID-19) were reported till November 21, 2021, across the globe.

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the Asia Pacific generic oncology sterile injectable market growth. Many surgeries are currently postponed due to COVID-19 crisis, in order to ensure safety of the patients. Supply chain and manufacturing activities in India, China, the U.S., and others have been disrupted due to lockdowns. Whereas, the countries such as Thailand, Indonesia, Singapore, and others are facing problems with transportation of raw materials for manufacturing pharmaceutical products.

Browse 37 Market Data Tables and 30 Figures spread through 181 Pages and in-depth TOC on Asia Pacific Generic Oncology Sterile Injectable Market, by Drug Type (Monoclonal Antibodies, Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific)

To know the latest trends and insights prevalent in the Asia Pacific generic oncology sterile injectable market, click the link below:

https://www.coherentmarketinsights.com/market-insight/asia-pacific-generic-oncology-sterile-injectable-market-4839

Market players are focusing on various inorganic growth strategies such as partnerships and collaborations, which is expected to boost the market growth over the forecast period. For instance, in 2017, Baxter International, a multinational health care company, entered into strategic partnership with ScinoPharm Taiwan Ltd, a leading high quality API supplier, to develop, manufacture, and commercialize five injectables used in oncology treatments.

Key Takeaways of the Asia Pacific Generic Oncology Sterile Injectable Market:

• The Asia Pacific generic oncology sterile injectable market is expected to exhibit a CAGR of 12.2% over the forecast period (2021-2028). Japan is expected to hold dominant position in the generic oncology sterile injectable market, owing to emergence of generic drugs manufactured by regional manufacturers to curb the drug shortage crisis, which resulted in the unavailability of major cancer drugs for treatment in the healthcare facilities.
• Among disease indication, others segment is expected to account for major market share over the forecast period, owing to increasing prevalence of various cancers such as leukemia, bone cancer, and others. For instance, according to the American Society of Clinical Oncology, the U.S. is estimated to witness 3,610 new cases of bone cancer and 2,060 deaths due to bone cancer in 2021.
• Some of the major players operating in the Asia Pacific generic oncology sterile injectable market include Eli Lily and Company, Biocon Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Baxter International Inc., Hikma Pharmaceuticals, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.